2019
The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN)
Perreault S, McManus D, Bar N, Foss F, Gowda L, Isufi I, Seropian S, Malinis M, Topal JE. The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN). Transplant Infectious Disease 2019, 21: e13059. PMID: 30737868, DOI: 10.1111/tid.13059.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAnti-Bacterial AgentsAntimicrobial StewardshipFebrile NeutropeniaFemaleHematopoietic Stem Cell TransplantationHumansMaleMedication Therapy ManagementMethicillin-Resistant Staphylococcus aureusMiddle AgedNoseRetrospective StudiesStaphylococcal InfectionsTime FactorsVancomycinYoung AdultConceptsHematopoietic stem cell transplant recipientsPost-intervention cohortFebrile neutropeniaVancomycin useVancomycin discontinuationStewardship teamRetrospective analysisMultimodal approachStem cell transplant recipientsResistant Gram-positive organismsResistant Gram-positive infectionsAntibiotic stewardship teamDiscontinuation of vancomycinEvidence of pneumoniaPost-implementation cohortPrevious MRSA infectionCell transplant recipientsGram-positive infectionsNasal swab collectionEmpiric vancomycinFN patientsVancomycin ordersVancomycin usageHSCT recipientsTransplant recipients
2014
Clinical and Laboratory Factors That Predict Death in Very Low Birth Weight Infants Presenting With Late-onset Sepsis
Levit O, Bhandari V, Li FY, Shabanova V, Gallagher PG, Bizzarro MJ. Clinical and Laboratory Factors That Predict Death in Very Low Birth Weight Infants Presenting With Late-onset Sepsis. The Pediatric Infectious Disease Journal 2014, 33: 143-146. PMID: 24418836, PMCID: PMC3917323, DOI: 10.1097/inf.0000000000000024.Peer-Reviewed Original ResearchConceptsLate-onset sepsisLow birth weight infantsBirth weight infantsIndependent risk factorLaboratory factorsWeight infantsVLBW infantsRisk factorsCases of LOSEpisodes of LOSRisk of LOSFungal LOSNeonatal intensive care unitMultivariate logistic regression analysisSepsis-related deathsIntensive care unitOnset of illnessSepsis-associated mortalityGram-positive infectionsLogistic regression analysisOnset of diseasePresentation of illnessComposite risk profileLaboratory signsNecrotizing enterocolitis
2001
Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria
Bassetti M, Dembry L, Farrel P, Callan D, Andriole V. Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and beta-lactams against gram-positive bacteria. Diagnostic Microbiology And Infectious Disease 2001, 41: 143-148. PMID: 11750168, DOI: 10.1016/s0732-8893(01)00298-x.Peer-Reviewed Original ResearchConceptsAmoxicillin/clavulanic acidPiperacillin/tazobactamClavulanic acidMethicillin-susceptible S. aureusPenicillin-nonsusceptible Streptococcus pneumoniaeMethicillin-sensitive S. epidermidisMethicillin-resistant coagulase-negative staphylococciGram-positive infectionsViridans group streptococciCoagulase-negative staphylococciPromising new fluoroquinoloneActive agentsNew fluoroquinoloneStreptococcal isolatesGroup streptococciVitro antibacterial activityClinical isolatesStreptococcus pneumoniaeComparative antimicrobial activityStaphylococcal isolatesClinical useEnterococcal isolatesImipenemGatifloxacinE. faecalis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply